Effect of a somatostatin analogue (SMS 201–995) on renal function and urinary protein excretion in diabetic rats

The Journal of diabetic complications Pub Date : 1991-04-01 DOI:10.1016/0891-6632(91)90066-X

Kazumasa Igarashi, Asao Nakazawa, Nagayuki Tani, Masatoshi Yamazaki, Seiki Ito, Akira Shibata

{"title":"Effect of a somatostatin analogue (SMS 201–995) on renal function and urinary protein excretion in diabetic rats","authors":"Kazumasa Igarashi, Asao Nakazawa, Nagayuki Tani, Masatoshi Yamazaki, Seiki Ito, Akira Shibata","doi":"10.1016/0891-6632(91)90066-X","DOIUrl":null,"url":null,"abstract":"<div><p>We evaluated the effect of a somatostatin analogue (SMS 201–995) on diabetic nephropathy using urinary albumin excretion as a marker in a streptozocin-induced diabetic unilateral nephrectomized rat model. Nondiabetic rats were injected with either 0.9% sodium chloride (NaCl) (n = 10) or SMS (n = 10). Diabetic rats were also injected with either 0.9% NaCl (n = 10) or SMS (n = 10). The control saline and SMS groups showed significant increases in urinary albumin excretion (UAE) and albumin clearance. The diabetic saline-treated rats showed no significant changes in UAE or albumin clearance. The diabetic SMS-treated rats showed significant decreases in UAE (151 ± 76 mg/day/kg to 98 ± 46, <em>P</em> < .005) and albumin clearance (5.85 ± 3.34 mL/day/kg to 3.63 ± 1.73, <em>P</em> < .01). There was no significant difference in kidney weight between the two control groups, but a significant difference was found between the two diabetic groups (3.35 ± 0.39 g vs. 2.68 ± 0.26 g, <em>P</em> < .001). The results suggest that in early diabetes with renal hyperfiltration and hypertrophy, the administration of SMS may prevent progression to late diabetic nephropathy.</p></div>","PeriodicalId":77636,"journal":{"name":"The Journal of diabetic complications","volume":"5 2","pages":"Pages 181-183"},"PeriodicalIF":0.0000,"publicationDate":"1991-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0891-6632(91)90066-X","citationCount":"10","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of diabetic complications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/089166329190066X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 10

Abstract

We evaluated the effect of a somatostatin analogue (SMS 201–995) on diabetic nephropathy using urinary albumin excretion as a marker in a streptozocin-induced diabetic unilateral nephrectomized rat model. Nondiabetic rats were injected with either 0.9% sodium chloride (NaCl) (n = 10) or SMS (n = 10). Diabetic rats were also injected with either 0.9% NaCl (n = 10) or SMS (n = 10). The control saline and SMS groups showed significant increases in urinary albumin excretion (UAE) and albumin clearance. The diabetic saline-treated rats showed no significant changes in UAE or albumin clearance. The diabetic SMS-treated rats showed significant decreases in UAE (151 ± 76 mg/day/kg to 98 ± 46, P < .005) and albumin clearance (5.85 ± 3.34 mL/day/kg to 3.63 ± 1.73, P < .01). There was no significant difference in kidney weight between the two control groups, but a significant difference was found between the two diabetic groups (3.35 ± 0.39 g vs. 2.68 ± 0.26 g, P < .001). The results suggest that in early diabetes with renal hyperfiltration and hypertrophy, the administration of SMS may prevent progression to late diabetic nephropathy.

查看原文本刊更多论文

生长抑素类似物(SMS 201-995)对糖尿病大鼠肾功能和尿蛋白排泄的影响

我们评估了生长抑素类似物(SMS 201-995)对糖尿病肾病的影响，在链脲佐菌素诱导的糖尿病单侧肾切除大鼠模型中使用尿白蛋白排泄作为标记。非糖尿病大鼠分别注射0.9%氯化钠(NaCl) (n = 10)或SMS (n = 10)。糖尿病大鼠同时注射0.9% NaCl (n = 10)或SMS (n = 10)。对照生理盐水组和SMS组尿白蛋白排泄(UAE)和白蛋白清除率显著增加。糖尿病盐处理大鼠的UAE和白蛋白清除率没有明显变化。糖尿病sms治疗大鼠的UAE(151±76 mg/天/kg)显著降低至98±46,P <白蛋白清除率(5.85±3.34 mL/天/kg至3.63±1.73,P <. 01)。两组间肾脏重量无显著性差异，但两组间存在显著性差异(3.35±0.39 g vs. 2.68±0.26 g, P <措施)。结果表明，在早期伴有肾脏超滤过和肥厚的糖尿病患者中，给予SMS可以预防进展为晚期糖尿病肾病。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

The Journal of diabetic complications

自引率

0.00%

发文量